Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease

Marla C. Dubinsky, Joel Rosh, William Alvis Faubion, Jaroslaw Kierkus, Frank Ruemmele, Jeffrey S. Hyams, Samantha Eichner, Yao Li, Bidan Huang, Nael M. Mostafa, Andreas Lazar, Roopal B. Thakkar

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Background: The efficacy of adalimumab in inducing and maintaining remission in children with moderately to severely active Crohn's disease was shown in the IMAgINE 1 trial (NCT00409682). As per protocol, nonresponders or patients experiencing flare(s) on every other week (EOW) maintenance dosing could escalate to weekly dosing; we aimed to determine the therapeutic benefits of weekly dose escalation in this subpopulation. Methods: Week 52 remission and response rates were assessed in patients who escalated to weekly dosing from their previous EOW schedule, which was according to randomized treatment dose (higher dose [HD] adalimumab [≥40 kg, 40 mg EOW;

Original languageEnglish (US)
Pages (from-to)886-893
Number of pages8
JournalInflammatory Bowel Diseases
Volume22
Issue number4
DOIs
StatePublished - Mar 9 2016

    Fingerprint

Keywords

  • adalimumab
  • disease flare
  • dose adjustment
  • dose escalation
  • pediatric Crohn's disease

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Dubinsky, M. C., Rosh, J., Faubion, W. A., Kierkus, J., Ruemmele, F., Hyams, J. S., Eichner, S., Li, Y., Huang, B., Mostafa, N. M., Lazar, A., & Thakkar, R. B. (2016). Efficacy and safety of escalation of adalimumab therapy to weekly dosing in pediatric patients with Crohn's disease. Inflammatory Bowel Diseases, 22(4), 886-893. https://doi.org/10.1097/MIB.0000000000000715